Suchergebnisse - "Chemotherapy, Adjuvant"

PubPharm (19)

1

Adjuvant Chemotherapy De-Escalation with Genomic Assay Protocol in Patients with Early Breast Cancer: A Single-Centre Prospective Cohort Study

in: Acta Médica Portuguesa | 2023

von Diogo Martins-Branco | Sofia Cristóvão Ferreira | Emanuel Gouveia | +4

2

乳腺癌新辅助化疗的现状与进展——南方乳腺癌论坛主要议题与共识 : = Current status and development of chemotherapy of breast cancer: the main topics and agreements of China South Breast Cancer Symposium

enthalten in: Zhong guo pu tong wai ke za zhi | 2019-11-04 17:09

China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health

von 蔡耿喜 | 蔡子杰 | 陈前军 | +5

3

A Structural Model for Chemotherapy Related Cognitive Impairment and Quality of Life in Breast Cancer Patients

enthalten in: Journal of Korean Academy of Nursing | 2019

von Lee, J. | Oh, P.

4

Trastuzumab emtansine for residual invasive HER2-positive breast cancer

enthalten in: The New England journal of medicine | 2019

von Minckwitz, G. | Huang, C. | Mano, M. | +26

5

Gene signatures for breast cancer, clinical utility and therapeutic applications

enthalten in: Revista medica del Instituto Mexicano del Seguro Social | 2018

von Vargas-Aguilar, V. | Arroyo-Alvarez, K.

6

A high-risk 70-gene signature is not associated with the detection of tumor cell dissemination to the bone marrow

enthalten in: Breast cancer research and treatment | 27 January 2018

von Walter, V. | Wallwiener, M.

7

Gene expression tests for women with early stage breast cancer : a review of clinical utility and cost-effectiveness

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, October 16, 2017

Rapid response report: summary with critical appraisal

Version 1.0.

von Narain, T. | Adcock, L.

8

Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia : Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer

enthalten in: ClinicalTrials.gov | 2016

9

Adjuvant FEC Versus EP in Breast Cancer (MIG5) : Fluorouracil, Epirubicin and Cyclophosphamide Versus Concurrent Epirubicin and Paclitaxel in Node Positive Early Breast Cancer Patients: a Randomized, Phase III Trial of Gruppo Oncologico Nord-Ovest - Mammella Intergruppo Group

enthalten in: ClinicalTrials.gov | 2015

10

Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative : a review of clinical effectiveness and guidelines

Erschienen: [Ottawa], Canadian Agency for Drugs and Technologies in Health, 20 February 2014

Rapid response report: summary with critical appraisal